China is emerging as a pharmaceutical innovation hub, transitioning from copycat drugs to cutting-edge research and development, rivaling global giants. US-based SAI MedPartners launched the China Pharmaceutical Innovation and Invention Index, recognizing Chinese companies for their shift to true innovation in drug development, with savings up to US$4 billion compared to global costs.
Companies like Hengrui in China boast efficient drug development, with costs close to US$1 billion versus the global average of US$5 billion. China is attracting global players for novel assets, particularly in oncology, where half of branded products may have expired patents by 2030. Early-stage biotech companies in China are leading large clinical trials, setting them apart from counterparts in Europe and the US.
Jiangsu Hengrui Pharmaceuticals and BeOne top the Chinese index, excelling in innovation and invention categories. BeOne’s zanubrutinib achieved global sales of US$2.6 billion, becoming a leader in the BTK inhibitor class. China’s focus on innovation is evident in its progress towards antibody-drug conjugates and CAR-T therapies for cancer treatment.
Chinese government support is catalyzing innovation in drug development, from regulatory approvals to reimbursement policies in hospitals. Commercial insurers are now part of national drug reimbursement discussions, further propelling the growth of pharmaceutical innovation in China. Rising stars in the field include Alphamab Oncology, DualityBio, and Harbour BioMed, showcasing China’s potential on the global stage.
While Chinese pharmaceutical companies are not yet household names like Huawei or BYD, they are making significant strides in licensing agreements and global collaborations. China’s pharmaceutical industry is on the path to global recognition, with increased innovation, co-development opportunities, and licensing agreements. 1. The stock market reached record highs today, with the S&P 500 closing at 3,500 for the first time in history. The Dow Jones Industrial Average also saw gains, closing at 28,645. The surge was driven by positive economic data and optimism around a potential COVID-19 vaccine.
2. In other news, the unemployment rate fell to 8.4% in August, down from 10.2% in July. This marks the fourth consecutive month of decline in the jobless rate since the peak in April. However, experts caution that the recovery may be slowing down as some industries continue to struggle.
3. A new study published in a leading medical journal found that wearing a face mask can significantly reduce the transmission of COVID-19. Researchers analyzed data from various countries and concluded that mask-wearing can reduce the risk of infection by up to 85%. The findings support the importance of mask mandates.
4. Hurricane Laura made landfall in Louisiana as a Category 4 storm, causing widespread damage and leaving thousands without power. The storm brought heavy rain, strong winds, and storm surges, leading to flooding and destruction in several coastal areas. Emergency responders are working to assess the damage and provide assistance to those affected.
Read more at Yahoo Finance: China’s pharmaceutical sector moves into the big leagues as a global innovation powerhouse